Patent Law Weblog
recent posts
- USPTO Moves to Protect Design Rights for Digital Innovations
- Judicial Conduct and Disability Committee Has Its Say, Denies Judge Newman’s Latest Request for Review
- PTAB Issues Judgment on Priority in CRISPR Interference
- Parties File Supplemental Priority Statements in CRISPR Interference
- Why the Alice Test is Stupid, Part V: The Goalposts Keep Moving
about
Month: May 2013
-
By Donald Zuhn — Patent services provider inovia announced the release of its 2013 report on global patent and IP trends today. In compiling the report, inovia, which produces products for PCT national phase entry, European patent validation, and patent translations, surveyed 125 U.S. companies and universities in January 2013 to identify the trends having…
-
By Donald Zuhn — On March 28, the Federal Circuit in Rubin v. General Hospital Corp. affirmed judgment by the District Court for the District of Massachusetts dismissing the suit brought by Drs. Berish Rubin and Sylvia Anderson against The General Hospital Corporation requesting correction of U.S. Patent Nos. 7,388,093 and 7,407,756, which are assigned…
-
By Donald Zuhn — On March 25, the Federal Circuit in Dawson v. Dawson affirmed a determination by the Board of Patent Appeals and Interferences that the University of California, San Francisco (UCSF) failed to establish sole conception by Dr. Chandler Dawson of the claimed inventions in two patents assigned to InSite Vision Inc. The…
-
By Sherri Oslick — About Court Report: Each week we will report briefly on recently filed biotech and pharma cases. Eisai R&D Management Co., Ltd. v. Rea1:13-cv-00548; filed May 2, 2013 in the Eastern District of Virginia Review and correction of the patent term adjustment calculation made by the U.S. Patent and Trademark Office for…
-
May 7-8, 2013 – Paragraph IV Disputes (American Conference Institute) – New York, NY May 13-14, 2013 – Generics and Patent Strategies (SMi) – London, UK May 14, 2013 – Forum on Pharma & Biotech Collaborations (C5 (UK)) – Frankfurt, Germany May 14-16, 2013 – Fundamentals of Patent Prosecution 2013: A Boot Camp for Claim…
-
By Kevin E. Noonan — One of the most compelling arguments in the gene patenting debate with the public has been the cost of the Myriad BRCA gene test: $3,000 per test, a price that many without insurance coverage cannot afford. The argument rarely is embedded within a comparison with other tests, and is presented…
-
By Andrew Williams — Can a method of treatment claim be inherent in the prior art if neither the formulation nor the method of using the formulation twice a day were in the prior art? Earlier today, the Federal Circuit determined in Allergen v. Sandoz that a claimed method for treating glaucoma (which differed from the…
Patent Docs 